



**Catalog Number:** PR27263

**Product Type:** Recombinant Protein

**Source:** *E. Coli*

**Amino Acid Sequence:** MGSSHHHHHH SSSLVPRGSH MGSMLQNVTP HNKLPGEGNA GLLGLGPEAA APGKRIRKPS LLYEGFESPT MASVPALQLT PANPPPPEVS NPKKPGRVTN QLQYLHKVVM KALWKHQFAW PFRQPVDVAVK LGLPDYHKII KQPMDMGTIK RRLENNYYWA ASECMQDFNT MFTNCYIYNK PTDDIVLMAQ TLEKIFLQKV ASMPQEEQEL VVTIPKNSHK KGAKLAALQG SVTSAHQVPA VSSVSHTALY TPPPEIPTTV LNIPHPSVIS SPLKSLHSA GPPLAVTAA PPAQPLAKKK GVKRKADTTT PTPTAILAPG SPASPPGSLE PKAARLPPMR RESGRPIKPP RKDLPDSQQQ HQSSKKGKLS EQLKHCNGIL KELLKSKHAA YAWPFYKPVD ASALGLHDYH DIIKHPMDLS TVKRKMENRD YRDAQEFAAD VRLMFSNICYK YNPPDHDVVA MARKLQDVFE FRYAKMPD.

**Description/Molecular Mass:** Bromodomain Containing 2, also known as BRD2 is a transcriptional regulator which is a member of the BET, bromodomains and extra terminal domain, family of roteins. BRD2 links with transcription complexes and it acetylated chromatin in the course of mitosis, and it selectively binds o the acetylated lysine-12 residue of histone H4 through its two romodomains. BRD2 maps to the major histocompatibility complex MHC class II region on chromosome 6p21.3, however sequence comparison advocate that the protein is not implicated in the immune response. BRD2 has been implicated in juvenile myoclonic epilepsy, a common form of epilepsy which grows to be visible in adolescence.

BRD2 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 478 amino acids (1-455 a.a) and having a molecular mass of 52.8kDa.

BRD2 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

**Purity:** Greater than 90.0% as determined by:  
(a) Analysis by SDS-PAGE.

**Format:** BRD2 protein solution (1mg/ml) containing Phosphate buffered saline (pH7.4), 10% glycerol and 1mM DTT.

**Storage:** Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles.

### FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

03/08v1

[www.neuromics.com](http://www.neuromics.com)

Neuromics • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail [pshuster@neuromics.com](mailto:pshuster@neuromics.com)